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A milestone in cannabis research is the establishment of a clinically relevant cannabis
withdrawal syndrome, yet little is known about the underlying mechanisms. We
investigated the predictive role of mental health and cognitive factors in withdrawal
severity during an active attempt to cut down, relative to uninterrupted cannabis use.
Ninety heavy cannabis users were randomly assigned to an experimental or control
group. The experimental group was asked to cut down substance use for 1 week.
Past week substance use, substance use-related problems, depressive symptoms,
cravings, and cognitive control were assessed at baseline. Past week substance
use and withdrawal severity were assessed at follow-up. The experimental group
reduced their cannabis use more and experienced more withdrawal than the control
group. Hierarchical regression analysis per predictor indicated that cannabis use-related
problems, depressive symptoms, and cannabis craving, but not cognitive control,
predicted stronger withdrawal. Craving uniquely predicted withdrawal in the experimental
group. A combined hierarchical regression indicated that only depressive symptoms
and cannabis use-related problems uniquely predicted withdrawal across groups. These
results suggest that depressive symptoms and cannabis use-related problems are
generally indicative of cannabis withdrawal severity, whereas craving specifically predicts
cannabis withdrawal during an active attempt to cut-down cannabis use.
Keywords: cannabis, cognitive control, cannabis use disorder, craving, depression, withdrawal
INTRODUCTION
One of the milestones in cannabis research is the establishment of a clinically relevant cannabis
withdrawal syndrome (1). As such, cannabis withdrawal is a new diagnostic criterion for cannabis
use disorders (CUDs) in the latest edition of the diagnostic statistical manual [DSM-5; (2)].
Cannabis withdrawal refers to mental (e.g., mood swings, sleep disruptions) and physical (e.g.,
headaches, nausea) discomfort that cannabis users may experience after discontinuation or
reductions in use. Supporting the maintenance of addictive behaviors, poor cognitive functioning
and mental health may play an important role in the severity of mental discomfort during
withdrawal. However, little is still known about the underlying mechanisms. We therefore assessed
the role of both cognitive andmental health factors in the subjective severity of cannabis withdrawal
during an active attempt to cut down cannabis use in heavy cannabis users.
Cousijn and van Duijvenvoorde Predictors of Cannabis Withdrawal Severity
Given the recognized role of withdrawal in relapse, withdrawal
reduction was one of the primary targets for the development
of pharmacotherapies for substance use disorders (SUDs)
over the past decades (3). The existence of withdrawal after
discontinuation of cannabis use has long been questioned,
paralleling the lack of pharmacotherapies approved for treating
CUDs (4). However, the past decades, many studies confirmed
withdrawal is common in both treatment and non-treatment
seeking cannabis users [for reviews see (5, 6)]. Moreover, there
appears to be a bidirectional relationship between withdrawal
and dependence severity; That is, higher CUD severity has been
found to predict more severe withdrawal [e.g., (7, 8); but see
(9)] and more severe withdrawal has been found to predict more
severe future dependence (10). It has also repeatedly been shown
that cannabis users who experience more severe withdrawal
during a quit attempt reinitiate use sooner (8, 11–13). Finally,
withdrawal has been found to be higher in individuals with more
severe depressive symptoms (7, 14).
Although not all users will experience withdrawal (9),
cannabis withdrawal generally peaks within the first week of
abstinence and predicts relapse (8, 13, 15). Most previous studies
specifically investigated the mechanisms underlying cannabis
withdrawal during an attempt to remain abstinent. However,
daily fluctuations in withdrawal symptoms are thought to play
a prominent role in non-abstinent users as well; The acute
withdrawal symptoms that emerge after using induce a state
of negative affect that, in turn, increases the motivation to use
again (16, 17). In line with this, using frequent daily withdrawal
assessments in heavy non-abstinent cannabis users, it has been
shown that cannabis withdrawal increases just prior to cannabis
use (18). As such, to help us understand who is at a greater risk
of relapse after abstinence, an important next step is to reveal
predictors of withdrawal severity during an active attempt to
cut-down cannabis use compared to uninterrupted cannabis use.
Theoretical models of addiction suggest that, beside
withdrawal severity, poor cognitive control over the extremely
strong motivations to use (e.g., craving) is thought to play
a key role in the development and maintenance of SUDs
(16, 19–23). Few studies specifically investigated the role of
craving and cognitive control in CUDs, however, there is
preliminary evidence that both processes play a prominent
role in the development of CUDs and relapse. Craving is a
complex multifaceted process that represents the extreme urge
to use drugs commonly experienced during abstinence (17).
Exposure to cannabis-related cues can also induce craving
in individuals with a CUD (24, 25) and craving can predict
treatment outcomes in adolescents with a CUD (26). Regarding
cognitive control, cannabis intoxication can temporarily impair
planning, organizing, problem solving, decision-making,
memory, and emotional control (27). Although contradictory
findings have been reported, CUDs are associated with similar
impairments in cognitive control (28, 29) and withdrawal during
abstinence parallels a temporarily (further) decline (30, 31).
Neural activity in brain areas involved in cognitive control
may predict escalation of cannabis use in heavy cannabis users;
Using the Iowa Gabling Task, higher win-related activity in the
superior frontal gyrus and higher activity during the anticipation
of disadvantageous decisions in the frontal pole were found
to be associated with an increase in weekly cannabis use 6
months later (32). Similarly, using the N-Back working-memory
task, functionality of the fronto-parietal executive network also
predicted changes in cannabis use (33). Interestingly, better
cognitive control as measured with the classical Stroop (34) has
been found to relate to less cannabis cue-induced craving in
heavy cannabis users (35). Further supporting the link between
cognitive control and craving, higher neural activity in brain
areas involved in cognitive control in response to watching
cannabis cues related to less craving in heavy cannabis users (36).
Although the association between withdrawal severity, mental
health problems and treatment outcomes is evident (6–9), the
association between cognition and cannabis withdrawal severity
is unclear. The above described preliminary findings of the
association between cognition and cannabis use suggest that
cognitive factors including craving and cognitive control, as well
the severity of CUD-relatedmental health problems like cannabis
use-related problems and depression can predict withdrawal
severity during an active attempt to cut down or quit cannabis
use. More specifically, better cognitive control may help in
actively reducing the motivation to use cannabis and mental
discomfort from withdrawal, and withdrawal may temporarily
lower cognitive control. In turn, higher baseline craving and, as
suggested by previous studies (7, 8, 14), especially severity of
depressive symptoms and CUD may increase the likelihood to
experience withdrawal.
To test this hypothesis, craving, cognitive control [Classical
Stroop (34) and Colombia Card Test (37)], substance use-
related problems (cannabis, nicotine, alcohol), and symptoms
of depression were assessed in a large group of almost daily
cannabis users during a baseline laboratory test session. Given the
presumed role of cannabis withdrawal severity in continued daily
cannabis use, as well as relapse after abstinence, it is important
to study predictors of withdrawal in cannabis users who try to
lower their use compared to those who continue their use. To
specifically investigate withdrawal during an active attempt to cut
down vs. uninterrupted cannabis use, the heavy cannabis users
were randomly assigned to an experimental or control group.
The experimental group was explicitly instructed to use as little
cannabis and other substances during following week. Substance
use and withdrawal severity of that week were subsequently
assessed through a telephone interview exactly 1 week later.
Given the multifaceted complex nature of cognitive control and
the relevance of emotional control for addiction, both a relatively
cold, emotion devoid, general executive functioning task (Stroop)
and a relatively hot emotional decision making task (CCT)
were included in the design. We expected (i) baseline craving,
cannabis use-related problems, and symptoms of depression to
be positively related to more severe withdrawal, and (ii) cognitive
control to be negatively related to more severe withdrawal.
MATERIALS AND METHODS
Participants
Ninety-three heavy cannabis users (21 females; 18–31 years)
were recruited at educational institutions and in Dutch cannabis
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outlets. Heavy cannabis use was defined as smoking cannabis
more than 3 days a week for at least 1 year and having a
Cannabis Use Disorder Identification Test-Revised [CUDIT-R;
(38)] score of ≥10. Approximately 95% percent of the cannabis
users that score 10 or more on the CUDIT-R have a CUD
(38). Potential participants were excluded if they currently used
psychotropic medication or had a treatment history for any
psychiatric disorder. All participants signed informed consents
and the local Ethics Committee of Leiden University approved
all procedures in this study. Of the 93 participants, three were
excluded from further analyses due to technical problems. The
final sample thus included 90 heavy cannabis users (Table 1).
Questionnaires on Substance Use,
Craving, and Psychological Functioning
Cannabis craving was assessed with the 12-item Marijuana
Craving Questionnaire-Short Form [MCQ-SF; (39)] at the start
of the baseline test-session. The MCQ-SF assesses various
dimensions of craving (e.g., expected positive outcomes, desire
to use and intention to use) on a 7-point scale ranging from
“strongly disagree” (1) to “strongly agree” (7). Total craving
score was obtained by averaging all item scores. The Timeline
Follow-Back (TLFB) was used to measure cannabis, alcohol,
cigarette and other substance use during the past 7 days at
baseline and follow-up (40). The 8-item CUDIT-R was used
to measure severity of cannabis use-related problems during
the past 6 months at baseline (38). The CUDIT-R assesses the
frequency of cannabis use, symptoms of dependence and other
psychological problems, scaled from never (0) to almost daily
(4). Total CUDIT-R score was obtained by summing all item
scores. The 10-item Alcohol Use Disorder Identification Test
(AUDIT) was used to measure severity of alcohol use-related
problems during the past 6 months at baseline (41). Moreover,
the 6-item Fagerstrom Test for Nicotine Dependence (FTND)
was used to assess severity of nicotine dependence during the
past 6 months at baseline (42). The 21-item Beck Depression
Inventory (BDI) was used to measure symptoms of depression
at baseline (43). Finally, the 15-item Marijuana Withdrawal
Checklist (MWC) was used to assess cannabis withdrawal
symptom severity during the past week at follow-up (15). This
questionnaire assesses mental (e.g., depressed mood, irritability,
aggression) and physical (e.g., headaches, shakiness) symptoms
commonly associated with cannabis withdrawal. Participants can
also add additional symptoms they experienced. Participants
rated the severity of each symptom on a 4-point scale from “not
at all” (0) to “severe” (3). Total withdrawal severity was obtained
by summing severity ratings.
Cognitive Control Tasks
The validated Dutch paper version of the Classical Stroop Task
(34) and the computerized “hot” Columbia Card Task [CCT;
(37)] were adminstered. During the Stroop, participants first
TABLE 1 | Medians (SD) of sample characteristics and study measures in all participants at baseline (Complete sample), and for the participants that remained in the
study at follow-up (Control and Experimental Group, excluding drop-out).
Complete sample (n = 90) Control (n = 36, excluding drop-out) Experimental (n = 29, excluding drop-out)
Baseline Baseline Follow-up Baseline Follow-up
Female (%) 23 19 24
Age (years) 21.4 (18.3–28.3) 20.9 (18.3–25.7) 21.4 (18.3–28.3)
Cannabis use:
Days per week 6 (3–7) 6 (3–7) 6 (3-7)
TLFB, grams past week 2.7 (0.7–16.8) 4.3 (1.8–15.7) 3.2 (0.3–11.8) 5.2 (0.7–16.8) 2.4 (0–10)
CUDIT-R 17 (10–27) 16 (10–26) 17 (11–27)
Mixed joints with tobacco (%) 91 89 90
Alcohol use:
TLFB, glasses past week 10 (0–55.2) 11 (0–51.5) 12 (0–37) 10 (0–55.2) 4 (0–100)
AUDIT 11.5 (0–28) 11 (3–24) 12 (0–28)
Smoking:
Smokers (%) 72 64 72
TLFB, cigarettes past week 42.5 (0–161) 42 (0–160) 32 (0–195) 47 (0–161) 42 (0–160)
FTND 1 (0–7) 0 (0–7) 2 (0–7)
Depression (BDI) 7 (0–30) 5 (0–30) 8 (2–26)
Cognitive factors:
Cannabis craving (MCQ-SF) 3.2 (1.5–5.5) 3.2 (1.5–5.2) 3.2 (1.7–5.5)
Stroop Interference score (ms) 30.2 (11.7–54.1) 27.5 (11.7–54.1) 31.8 (13.8–52)
CCT n cards 9.6 (2.7–15) 8.5* (2.7–13.9) 10* (5.8–15)
Cannabis withdrawal at follow-up (MWC) – – 8* (0–21) – 11* (0–36)
Range is reported between brackets. TLFB, Timeline Follow Back; CUDIT-R, Cannabis Use Disorder Identification Test-Revised; AUDIT, Alcohol Use Disorder Identification Test; BDI,
Beck Depression Inventory; FTND, Fagerstrom Test for Nicotine Dependence; MCQ-SF, Marihuana Craving Questionnaire-Short Form; CCT, Columbia Card Task; MWC, Marihuana
Withdrawal Checklist. *significant group differences at p < 0.05.
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read aloud color words (i.e., blue, green, red, yellow) as fast
as possible printed in black ink, then named aloud colors
of solid colored patches, and finally read aloud color words
printed in an incongruent color (e.g., red printed in blue). The
difference between the congruent (first two) and incongruent
(last) subtasks was taken as a measure of cognitive control, with
high scores indicating more interference and therefore lower
cognitive control.
The CCT is a computerized card game with win and loss cards
during which participants are instructed to earn as much points
as possible. Each game round participants view 32 faced-down
cards and turn as many as they want before deciding to stop
the current round and cash the accumulated points. However,
if they turn a loss card they will lose points and the game
round ends. Points gained with a win card (10 or 30), points
lost with a loss card (250 or 750), and the number of loss cards
(1 or 3) varied. The average number of turned cards across 24
game rounds was used in subsequent analyses. The CCT was
made incentive compatible by instructing participants that their
scores of three randomly drawn rounds would be averaged and
summed together. This total score was used in a weighted lottery
procedure (see Procedure below).
Experimental Manipulation
The experimental group received the following instruction: “For
the coming week, please lower your cannabis, nicotine, alcohol and
other drug use as much as possible. Note that each joint, cigarette or
beer you use less is incredibly good. In a week I will call you to ask
how this went; this conversation will take approximately 15min.
In addition, we raffle 50 Euro among everyone who takes part in
this follow-up interview, irrespective of your cannabis, and other
drug use.” The control group was only told that they would be
contacted for a follow-up interview regarding their cannabis, and
other drug use, and that we raffled 50 Euros among the follow-up
participants.
Procedure
The experiment consisted of a baseline test-session and a
telephone follow-up interview. During the baseline test-session
participants first completed the MCQ-SF, followed by the Stroop
and CCT on a laptop. The remaining questionnaires were
filled out after the tasks in the following order; TLFB, CUDIT-
R, AUDIT, FTND, and BDI. The baseline test-session took
approximately 45min for which each participant received 7.50
Euro. Exactly 1 week after the test session, all participants were
contacted again for a short telephone interview that contained
first the TLFB followed by the MWC. A shopping voucher of 50
Euro was raffled among participants who completed the follow-
up interview. Participants were instructed that this lottery was
weighted upon their CCT score, with higher scores relating to
more chance to gain the 50 Euro voucher.
Statistical Methods
To assess sample characteristics and change in substance use
between the experimental and control group, independent
sample t-tests and repeated measures ANOVAs were used.
Although some of our variables are relatively skewed, these
tests are described as robust with respect to the assumption
of normality. This means that some deviation away from
normality does not have a large influence on Type I error
rates, particularly when group sizes are moderate to large and
relatively equally sized (44). When the equality of variance
assumption was violated, we report corrected degrees of freedom
and corrected t-values. Finally, we used hierarchical regression
analyses were used for testing predictors of withdrawal.
Inspection of residual probability plots indicated no violation
of assumptions of normality, linearity, and heteroscedasticity,
nor were there influential cases detected (maximum Cook’s
distance= 0.347).
RESULTS
Sample Characteristics at Baseline and at
1-Week Follow-Up
Attrition at follow-up was 28% and did not significantly differ
between the experimental (n = 17) and control (n = 8) group
[χ(1) = 3.2, p = 0.072]. Participants that dropped out differed
on none of the baseline measures from the participants that
remained in the study as indexed by independent sample t-test
comparisons (all p-values > 0.1), except on the CUDIT-R, which
was higher in the participants that dropped out [t(88) = −2.2,
p = 0.032]. All subsequent analyses were conducted excluding
the participants who dropped out at follow-up.
Independent t-tests were performed to test whether the
experimental and control group differed significantly on any
of the baseline measures. Results showed that the experimental
and control groups did not differ significantly in any of the
baseline measures, except CCT score, in which the experimental
group (M = 10.2, SD = 2.0) sampled more cards than the
control group (M = 8.6, SD = 2.4), t(63) = 2.99, p = 0.004.
As expected, the experimental group reported higher withdrawal
at follow-up than the control group [t(43.2) = 2.34, p = 0.024,
Cohen’s d = 0.63; Figure 1A]. Exploratory analyses of individual
withdrawal symptoms indicated that group differences weremost
apparent in physical [decreased appetite; t(39.7) = 2.93, p= 0.006]
andmental symptoms such as increased irritability [t(50.2) = 2.07,
p = 0.037], and strange dreams [t(44.1) = 2.28, p = 0.028], see
Figure 1B.
Next we aimed to assess if groups differed in their cannabis
use over time (Figures 1C–E). A repeated measure ANOVA
was performed with used grams per week (TLFB) at baseline
and follow-up as within-subject factor and group as between-
subject factor. Cannabis use was lower at follow-up [main effect
Time: F(1, 63) = 29.7, p < 0.001, partial η
2
= 0.32], and this
decline was larger for the experimental group [interaction effect
Time x Group: F(1, 63) = 6.9, p = 0.011, partial η
2
= 0.1; see
Figure 1C], indicating that participants indeed engaged in an
active attempt to cut down. Alcohol use did not differ between
sessions, nor was there an interaction effect between Time and
Group (ps > 0.3). Cigarette use was slightly lower at follow-up
independently of group [main effect Time: F(1, 63) = 4.4, p= 0.04,
partial η2 = 0.07; Figure 1E]. The absolute decline in cannabis
(r = −0.215, p = 0.09), cigarette (r = −0.030, p = 0.84), and
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FIGURE 1 | Mean levels of withdrawal (A), mean withdrawal score per symptom (B), cannabis use in the past week (C), alcohol use in the past week in standard
units (D), and smoking in the past week in number of cigarettes (E) at baseline and follow-up for the experimental and control group. Standard errors are plotted;
**p < 0.01, *p < 0.05; TLFB, Timeline Follow Back; MWC, Marijuana Withdrawal Checklist.
alcohol use (r = 0.046, p = 0.72) did not significantly correlate
with cannabis withdrawal.
Cannabis, cigarette, and alcohol use are highly comorbid
in the current sample (Table 1). Pairwise correlations were
computed to investigate the association between cannabis,
cigarette, and alcohol use (baseline TLFB, follow-up TLFB,
change in TLFB) and problem behavior related to substance use
(CUDIT-R, FTND, AUDIT). Cannabis use did not correlate with
cigarette (baseline: r = 0.132, p = 0.295; follow-up: r = 0.025,
p = 0.845) and alcohol use (baseline: r = 0.050, p = 0.691;
follow-up: r = 0.016, p = 0.902). Similarly, change in cannabis
use did not correlate with change in cigarette (r = 0.121,
p = 0.409) and alcohol use (r = 0.180, p = 0.173). Correlations
betweenmeasures of problem behaviors showed that the CUDIT-
R correlated significantly with the FTND (r = 0.363, p = 0.003),
but not with the AUDIT (r = 0.119, p= 0.344).
Predictors of Withdrawal
Pairwise correlations were computed between all predictors in
the participants who completed the entire study (Figure 2). The
BDI was moderately correlated with the CUDIT-R (r = 0.379,
p = 0.002) and craving (r = 0.417, p = 0.001). Moreover,
craving was weakly correlated with the CUDIT-R (r= 0.247, p=
0.047). The two cognitive control measures did not significantly
correlate with each other (Stroop-CCT r = 0.211, p = 0.091),
with mental health (Stroop-BDI r = 0.047, p = 0.709; Stroop-
CUDIT-R r = 0.051, p = 0.685; CCT-BDI r = 0.215, p = 0.085;
FIGURE 2 | Scatterplots for the relation between indices of mental-health
factors (Left), and craving and mental-health factors (Middle and Right).
BDI, Beck Depression Inventory; CUDIT-R, Cannabis Use Disorder
Identification Test-Revised; MCQ, Marijuana Craving Questionnaire.
CCT-CUDIT-R r = 0.089, p = 0.480), and with craving (Stroop-
craving r = 0.077, p= 0.543; CCT-craving r = 0.015, p= 0.904).
A first aimwas to assess if mental health, craving and cognitive
control predicted withdrawal severity (Figure 3). A second aim
was to assess if these effects were specific for an active attempt
to cut-down substance use. A hierarchical regression analysis was
performed per predictor of interest. For each of these regressions,
MWC score was the dependent variable. The main effect of the
predictor under study was entered first, after which a main effect
of group was entered in the second step, and finally an interaction
effect between group and predictor was added.
Higher CUDIT-R score was a significant predictor of
withdrawal (B = 0.75, SE = 0.2, p < 0.001, R2 = 18.1%). Adding
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FIGURE 3 | Scatterplots for the relation between level of withdrawal at follow-up and CUDIT-R (Left), Depression (Middle), and Craving (Right) score at baseline for
the experimental and control group separately. BDI, Beck Depression Inventory; CUDIT-R, Cannabis Use Disorder Identification Test-Revised; MCQ, Marijuana Craving
Questionnaire.
the main effect of group explained significantly more variance
[Fchange(1, 62) = 4.37, p = 0.04, R
2
= 23.5%], although there was
no significant group x CUDIT-R interaction (p= 0.64).
Higher BDI score also was a significant predictor of
withdrawal (B = 0.60, SE = 0.13, p < 0.001, R2 = 26%). Adding
group (B = −2.85, SE = 1.65, p = 0.089) as well as the group x
BDI interaction (B= 0.483, SE= 0.25, p= 0.062) did not explain
significantly more variance.
MCQ-SF score was a significant predictor of withdrawal
(B = 3.41, SE = 1.05, p = 0.002, R2 = 14.4%), indicating that
greater craving was predictive of greater cannabis withdrawal.
Adding the main effect of group [Fchange(1, 62) = 5.7, p = 0.02,
R2 = 21.6%], as well as a group x craving interaction
[Fchange(1, 61) = 5.5, p = 0.023, R
2
= 28.1%] explained
significantly more variance. Follow-up tests of this interaction
term indicated that greater craving predicted higher withdrawal
symptoms in the experimental (B = 5.27, SE = 1.55, p = 0.002),
but not in the control group (B= 0.64, SE= 1.22, p= 0.6).
Finally, cognitive control measures did not significantly
predict withdrawal symptoms in any of the models. That is,
CCT was not a significant predictor of withdrawal (B = 0.317,
SE = 0.389, p = 0.107). While there was a main effect of group
[Fchange(1, 62) = −4.49, p = 0.025], there was no group x CCT
interaction (B = −0.144, SE = 0.852, p = 0.866). Similarly,
Stroop was not a significant predictor of withdrawal (B = 0.054,
SE = 0.084, p = 0.522). While there was a main effect of group
[Fchange(1, 62) = 5.69, p= 0.02], there was again no group x Stroop
interaction (B=−0.012, SE= 0.166, p= 0.942).
Given the significant correlations between BDI, CUDIT-R and
craving, a combined hierarchical regression was performed to
assess the unique contribution of these significant predictors of
interest. Following the same approach as described above, first,
the main effects of all predictors were entered, then the main
effect of group was entered, and finally all interactions between
predictors x group were entered. When assessing the first step
of this analysis, the model was significant [Fchange(3, 61) = 10.86,
p < 0.001, R2 = 34.8%]. The main effects of each predictor in
this model (BDI, CUDIT-R, and craving) showed that higher
BDI (B = 0.401, SE = 0.14, p = 0.006) and higher CUDIT-
R (B = 0.444, SE = 0.20, p = 0.028) scores at baseline were
predictive of greater withdrawal at follow-up. Adding the main
effect of group in a second step did not yield a better model fit
(p = 0.10), as well adding all interactions between group and
these predictors did not improve model fit (p = 0.277) in a final
step.
Control Analyses
We performed two control analyses. First, to control for overlap
between the MWQ symptoms Depression and Craving and
our main predictors of interest BDI (Depression) and MCQ-SF
(Craving) we repeated all regression analyses with a withdrawal
(MWQ) score excluding these two items. All reported results
and interpretations remained the same, except for the BDI.
That is, BDI was a significant predictor for withdrawal severity
[Fchange(1, 63) = 20.18, p < 0.001, B = 0.50, SE = 0.11] yet
the interaction between group x BDI now reached significance
[Fchange(1, 61) = 4.4, p = 0.04]. Follow-up analyses showed that
BDI scores were more strongly related to withdrawal in the
experimental group [Fchange(1, 27) = 12.3, p = 0.002, B = 0.714,
SE = 0.20] than in the control group [Fchange(1, 34) = 4.77,
p= 0.036, B= 0.248, SE= 0.11].
Second, nicotine dependence (FTND) correlated positively
with cannabis use-related problems (CUDIT-R). To control for
a possible influence of nicotine dependence, we repeated all
regression analyses adding the FTND as an additional predictor
in the first step, and the interaction between group x FTND as
an additional predictor in the third step of the regression models.
All reported results and interpretations remained the same, and
no main or interaction effects of FTND were observed.
DISCUSSION
Not all individuals with a CUD who attempt to lower or quit
their cannabis use will experience severe withdrawal (9). From
a clinical perspective, predicting who will could help tailoring
treatment (e.g., decisions to commence pharmacological and/or
psychological withdrawal management). In this first study in
near-daily cannabis users, we investigated if cognitive (craving,
cognitive control) and mental health (depression, cannabis use-
related problems) factors could predict withdrawal severity
during an active attempt to cut down cannabis use. The
experimental group was asked to lower substance use as
much as possible in the week following the baseline test-
session and significantly reduced their cannabis use more
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and experienced more withdrawal compared to the control
group. Baseline cannabis use-related problems, depressive
symptoms and craving, but not cognitive control, significantly
predicted withdrawal at follow-up. Moreover, craving uniquely
predicted withdrawal severity in the experimental group.
Only depressive symptoms and cannabis-use-related problems
uniquely predicted withdrawal severity across groups. Together,
these factors explained 34.8% in the variance in cannabis
withdrawal 1 week later. For the first time we showed
that especially baseline depressive symptoms, cannabis use-
related problems and craving, but not cognitive control, could
be indicative of cannabis withdrawal. Severity of depressive
symptoms and cannabis use-related problems may thereby
predict general mental and physical discomfort from fluctuations
in cannabis use, whereas craving may specifically do so in
individuals who actively attempts to cut down cannabis use.
This study is a first step toward understanding the
mechanisms underlying cannabis withdrawal during an active
attempt to cut-down or quit cannabis use, generating important
new hypotheses about how different self-reported mental health
problems can uniquely contribute to self-reported cannabis
withdrawal severity; Regardless of the significant moderate
correlations between depressive symptoms and cannabis use-
related problems, both factors uniquely predicted withdrawal
severity across groups. Craving predicted withdrawal severity
more strongly in the group who attempted to lower their
cannabis use. This effect was no longer significant when
depressive symptoms and cannabis use-related problems were
entered into the regression model, indicating that the shared
variance of these factors with craving is probably driving the
interaction between group and craving. Importantly, to further
our understanding, these results should be followed up by
more in-depth pharmacological studies, including longitudinal
measures of withdrawal and objective biochemical measures of
cannabis, cigarette and alcohol use. A critical evaluation of the
design and the implications for theory and future studies is
outlined below.
A cannabis user is almost never only a cannabis user. This
is corroborated in the present study; 90% of the cannabis users
combined tobacco with cannabis in their joints, 72% of the
cannabis users were daily cigarette smokers, and cannabis use-
related problems correlated with nicotine dependence (r= 0.363)
and depressive symptoms (r = 0.379). Alcohol use did not
correlate with cannabis and cigarette use. Cannabis use was lower
at follow-up and this decline was larger for the experimental
group, indicating that participants indeed engaged in an active
attempt to cut down. However, cigarette use was also slightly
lower at follow-up independently of group. Cigarette use has been
shown to predict cannabis dependence over time, independently
from cannabis use frequency (45). Moreover, the pattern and
timeline of cannabis and nicotine withdrawal is suggested to be
similar and simultaneous abstinence may increase withdrawal
symptom severity (46). These results raise the question if
nicotine withdrawal and dependence are partly driving the
results. Cannabis use-related problems and depressive symptoms
uniquely predicted self-reported withdrawal severity after 1 week
and these results did not change when nicotine dependence
was additionally controlled for. Moreover, daily cigarette use
did not correlate with daily cannabis use (FTND) and the
change in cigarette use did not correlate with change in cannabis
use and withdrawal severity. These observations suggest that
nicotine withdrawal and dependence are not driving the result.
However, studies investigating the biochemical interactions
between cannabis and cigarette use and abstinence, and their
potential detrimental effects on clinical outcomes are needed to
further investigate this.
Following contemporary addiction models (16, 19–23) we
hypothesized that individuals with good cognitive control would
be better in suppressing withdrawal. Cognitive control did not
predict cannabis withdrawal, in contrast to mental health factors
and craving. These findings suggest that both relatively “cold”
executive functioning (Stroop) and relatively “hot” decision
making (CCT) are unrelated to withdrawal. The two control
measures did not correlate with each other and any of the
substance use measures in the sample that completed the
entire study (n = 65). However, post-hoc analyses in the entire
sample (n = 90) revealed a moderate correlation between
Stroop and CCT (r = 0.364, p < 0.001) and weak correlations
between craving and cognitive control (Craving-Stroop r= 0.242,
p = 0.022; Craving-CCT r = 0.207, p = 0.05), supporting
moderate construct and external validity of the CCT and Stroop.
To the best of our knowledge, there are no studies directly
investigating the association between cognitive control and
cannabis withdrawal. Interestingly, a meta-analysis investigating
the association between nicotine abstinence and cognitive
performance suggests that response inhibition is consistently
impaired by nicotine abstinence, but not cognitive control as
measured with the Stroop (47). Moreover, an fMRI study on
smoking abstinence suggested that particularly the regulation
of negative affect was related to abstinence (31). These studies
suggest that behavior and brain functioning during cognitive
tasks that measure (negative) emotion regulation and inhibition
may predicts cannabis withdrawal better than the Stroop and
CCT. However this hypothesis is speculative and future studies
are needed to further unravel the relationship between different
aspects of cognitive functioning and withdrawal.
Cannabis withdrawal symptoms include, irritability, anger or
aggression, depressive mood, anxiety, sleep difficulty (including
strange dreams), loss of appetite, restlessness, and discomforting
physical symptoms like tremors, headaches, sweating and
abdominal pain (2, 15). Importantly, depressive mood and
craving (on a 4-point scale) are symptoms of cannabis
withdrawal, showing some overlap with the BDI and craving
assessment, but these two items do not drive the results as the
effects are still significant and even stronger for the BDI when
the depressive mood and craving items are excluded from the
analyses. Moreover, explorative analyses of individual withdrawal
symptoms (Figure 1) indicated that the group difference in
withdrawal was mainly driven by strange dreams irritability and
decreased appetite. Unfortunately, we only assessed withdrawal
once after 1 week (close to the expected average peak of
withdrawal) (8, 13, 15). These results therefore reflect average
severity of each symptom across the week following the baseline
test-session. To assess the clinical merit of our results and to
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further investigate the association betweenmental health, craving
and withdrawal it essential to study individual withdrawal
symptoms over the course of abstinence in general population and
clinical samples of cannabis users.
As discussed above, withdrawal was only assessed once.
The current study also has other limitations that should be
acknowledged. The most important limitation is that we did
not include a biochemical verification of abstinence. In this
first study, we opted for a simple design, testing an ecologically
valid sample of cannabis users with comorbid substance use,
using behavioral tasks and self-reports that are generally available
to clinicians. Higher withdrawal combined with lower self-
reported cannabis use in the experimental compared to the
control group and the observed correlation between different
mental health assessments suggest that the self-reports and
procedures aremeaningful. However, without objectivemeasures
of substance use we cannot rule out the potential effect of a
social desirability bias induced by the testing procedure and
cannot properly investigate the interactions between withdrawal,
cannabis, cigarette and alcohol use. Although differentiating
new cannabis use from residual cannabis metabolites in urine
samples remains hard, statistical modeling tools using creatine
and 11-nor-9-carboxy-19-tetrahydrocannabinol (THCCOOH)
levels showed promising results and can aid in future studies (48).
Moreover, the mental-health factors included in this study
were limited to substance use-related problems and depression.
We specifically choose to only include depressive symptoms,
given that previous studies showed that only mood disorders
were related to the experience of significant withdrawal in heavy
adult cannabis users (14) and in treatment seeking adolescent
cannabis users (7). Yet, other mental health factors may play a
role withdrawal as well as both internalizing and externalizing
disorders are highly comorbid with CUDs and differentiate
between cannabis users with and without a CUD (49). Also,
dropout in the current study was 28% and those who dropped out
had significantly higher cannabis use-related problems than those
who participated in the follow-up. It is possible that difficulty
with decreasing cannabis use is related to the reachability of
those participants. Since selection effects may drive the current
findings, it is important for future studies to verify these findings
across different populations. The unexpected difference between
the groups on the CCT, should also be acknowledged. The
experimental group took more risky decisions than the control
group and this may have influenced our findings. Moreover, the
relative limited sample size is a limitation and studies in older
cannabis users are needed to determine of our effects generalize
to older age-groups. Finally, only a limited number of females
were tested, hindering us to assess potential differential impact
of sex on withdrawal [(50), but see (9, 12, 51, 52)]. Taken the
strengths and limitations of this study together, an important
next step is to study the role of a wider set of cognitive and
mental-health factors in individual trajectories of withdrawal, in
a well-balanced sample of males and females, both inside and
outside of a clinical setting, with the former having the advantage
of monitoring a broader group of heavy cannabis users, and the
latter having the advantage of monitoring cannabis abstinence
and participation in a more controlled setting.
In conclusion, we showed that baseline depressive symptoms,
cannabis use-related problems and craving, but not cognitive
control, could be indicative of cannabis withdrawal during an
attempt to cut down cannabis use. These findings generate
new hypotheses about how mental health and cognitive factors
may uniquely contribute to cannabis withdrawal. However, this
study did not include biochemical verifications of abstinence and
should be follow up by studies includingmore objective measures
of substance use and more frequent assessments of cannabis
withdrawal over time, both inside and outside of a clinical setting.
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